Xcout Intel
MDxHealth SA
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
Subscribe to see MDxHealth SA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MDxHealth SA at a glance
MDxHealth SA is a biotech company headquartered in Herstal, Belgium, founded in 2003. It is publicly listed (0O8G) with a market capitalisation of $131.2M. Xcout tracks 16 named people at MDxHealth SA, including Michael K. McGarrity (Chief Executive Officer & Executive Director).
MDxHealth SA leadership
- Michael K. McGarrityChief Executive Officer & Executive Director
- Ron KalfusInterim Chief Financial Officer
- John A. BellanoChief Commercial Officer
- John BellanoChief Commercial Officer
- Joseph SolleeExecutive Vice President of Corporate Development & General Counsel
- Kim LerouxExecutive Vice President of Revenue Cycle Management
10 more named people on record for MDxHealth SA, with roles, board committees and tenure — see the full roster →
MDxHealth SA funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | Undisclosed | 1 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
MDxHealth SA competitors
A few of MDxHealth SA's closest competitors — see the full list of competitors and alternatives →
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
EcoGenome LLC is a biotechnology company that develops diagnostic tests and kits for cancer, specifically focusing on prostate cancer. The company identifies individual tumor genetic vulnerabilities to help inform precise therapy planning and treatment choices for patients.
Get MDxHealth SA's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MDxHealth SA in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access